These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

129 related items for PubMed ID: 26595071

  • 1. Intrathecal rituximab for EBV-associated post-transplant lymphoproliferative disorder with central nervous system involvement unresponsive to intravenous rituximab-based treatments: a prospective study.
    Wu M, Sun J, Zhang Y, Huang F, Zhou H, Fan Z, Xuan L, Yu G, Guo X, Dai M, Feng R, Liu Q.
    Bone Marrow Transplant; 2016 Mar; 51(3):456-8. PubMed ID: 26595071
    [No Abstract] [Full Text] [Related]

  • 2. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
    Bonney DK, Htwe EE, Turner A, Kelsey A, Shabani A, Hughes S, Hughes I, Wynn RF.
    Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
    [Abstract] [Full Text] [Related]

  • 3. Intrathecal therapy with rituximab in central nervous system involvement of post-transplant lymphoproliferative disorder.
    Czyzewski K, Styczynski J, Krenska A, Debski R, Zajac-Spychala O, Wachowiak J, Wysocki M.
    Leuk Lymphoma; 2013 Mar; 54(3):503-6. PubMed ID: 22873830
    [Abstract] [Full Text] [Related]

  • 4. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Styczynski J, Gil L, Tridello G, Ljungman P, Donnelly JP, van der Velden W, Omar H, Martino R, Halkes C, Faraci M, Theunissen K, Kalwak K, Hubacek P, Sica S, Nozzoli C, Fagioli F, Matthes S, Diaz MA, Migliavacca M, Balduzzi A, Tomaszewska A, Camara Rde L, van Biezen A, Hoek J, Iacobelli S, Einsele H, Cesaro S, Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
    Clin Infect Dis; 2013 Sep; 57(6):794-802. PubMed ID: 23771985
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation.
    Takamatsu H, Araki R, Nishimura R, Yachie A, Espinoza JL, Okumura H, Yoshida T, Kuzushima K, Nakao S.
    J Clin Virol; 2016 Jul; 80():82-6. PubMed ID: 27218416
    [Abstract] [Full Text] [Related]

  • 6. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein-Barr virus reactivation after hematopoietic cell transplantation.
    Jain T, Kosiorek HE, Grys TE, Kung ST, Shah VS, Betcher JA, Slack JL, Leis JF, Khera N, Noel P, Palmer JM, Sproat LZ.
    Leuk Lymphoma; 2019 Jan; 60(1):110-117. PubMed ID: 29979906
    [Abstract] [Full Text] [Related]

  • 7. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
    Zallio F, Primon V, Tamiazzo S, Pini M, Baraldi A, Corsetti MT, Gotta F, Bertassello C, Salvi F, Rocchetti A, Levis A.
    Clin Transplant; 2013 Jan; 27(4):E491-7. PubMed ID: 23781897
    [Abstract] [Full Text] [Related]

  • 8. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
    Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
    Scand J Infect Dis; 2007 Jan; 39(3):235-44. PubMed ID: 17366054
    [Abstract] [Full Text] [Related]

  • 9. Monitoring of Epstein-Barr virus load after hematopoietic stem cell transplantation for early intervention in post-transplant lymphoproliferative disease.
    Meerbach A, Wutzler P, Häfer R, Zintl F, Gruhn B.
    J Med Virol; 2008 Mar; 80(3):441-54. PubMed ID: 18205222
    [Abstract] [Full Text] [Related]

  • 10. Heterogeneity in clinical course of EBV-associated lymphoproliferative disorder after allogeneic stem cell transplantation.
    Meyer SC, Medinger M, Halter JP, Baldomero H, Hirsch HH, Tzankov A, Dirnhofer S, Passweg JR, Tichelli A.
    Hematology; 2014 Jul; 19(5):280-5. PubMed ID: 24074746
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus-associated post-transplant lymphoproliferative disorder of plasma cell type following allogeneic haemopoietic stem cell transplant treated with rituximab.
    Getta B, Kwan J.
    Intern Med J; 2014 Aug; 44(8):821. PubMed ID: 25081050
    [No Abstract] [Full Text] [Related]

  • 12. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
    Kasow KA, Leung W, Horwitz EM, Woodard P, Handgretinger R, Hale GA.
    Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation.
    Nozzoli C, Bartolozzi B, Guidi S, Orsi A, Vannucchi AM, Leoni F, Bosi A.
    Leuk Lymphoma; 2006 Jan; 47(1):167-9. PubMed ID: 16321845
    [Abstract] [Full Text] [Related]

  • 14. Gastrointestinal tract involvement of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder after cord blood transplantation.
    Wakamatsu H, Akahane K, Kasai S, Watanabe A, Goi K.
    Pediatr Int; 2022 Jan; 64(1):e15233. PubMed ID: 35831256
    [No Abstract] [Full Text] [Related]

  • 15. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation.
    Twombley K, Pokala H, Ardura MI, Harker-Murray P, Johnson-Welch SF, Weinberg A, Seikaly M.
    Pediatr Transplant; 2012 Sep; 16(6):E201-9. PubMed ID: 22646132
    [Abstract] [Full Text] [Related]

  • 16. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation.
    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, Gualandi F, Bregante S, Ibatici A, di Grazia C, Dominietto A, Varaldo R, Bruno B, Frassoni F, Van Lint MT, Bacigalupo A.
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):901-7. PubMed ID: 20950702
    [Abstract] [Full Text] [Related]

  • 17. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
    Worth A, Conyers R, Cohen J, Jagani M, Chiesa R, Rao K, Goulden N, Veys P, Amrolia PJ.
    Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
    [Abstract] [Full Text] [Related]

  • 18. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
    Jiménez S.
    Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr virus polymerase chain reaction-negative stage IV post-transplant lymphoproliferative disorder in a heart transplant patient treated with rituximab.
    Garceau P, Couture C, Cantin B, Bernier V, Sénéchal M.
    J Heart Lung Transplant; 2008 Aug; 27(8):928-31. PubMed ID: 18656811
    [Abstract] [Full Text] [Related]

  • 20. [The efficacy and safety of rituximab in treatment of Epstein-Barr virus disease post allogeneic hematopoietic stem-cell transplantation].
    Xu LP, Liu DH, Liu KY, Zhang CL, Wang FR, Wang JZ, Wang Y, Chen H, Zhang YY, Yan CH, Han W, Chen YH, Zhao T, Zhang XH, Huang XJ.
    Zhonghua Nei Ke Za Zhi; 2012 Dec; 51(12):966-70. PubMed ID: 23327959
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.